Organogenesis Holdings Inc. Revenue Disclosure
3. Revenue
Revenue from Contracts with Customers
The following table sets forth revenue by product category:
|
|
Year Ended December 31, |
|
|||||||||
|
|
2025 |
|
|
2024 |
|
|
2023 |
|
|||
Advanced Wound Care |
|
$ |
531,242 |
|
|
$ |
453,639 |
|
|
$ |
405,514 |
|
Surgical & Sports Medicine |
|
|
31,788 |
|
|
|
28,404 |
|
|
|
27,626 |
|
Total net product revenue |
|
$ |
563,030 |
|
|
$ |
482,043 |
|
|
$ |
433,140 |
|
For all periods presented, net product revenue generated outside the United States represented less than 1% of total net product revenue.
For the years ended December 31, 2025, 2024, and 2023, the Company recorded GPO fees of $8,172, $6,102 and $5,623, respectively, as a direct reduction of product revenue.
Grant Income
During the second quarter of 2025, the Company received a grant from a governmental agency totaling $5,000 for the achievement of two milestones. The grant helps offset the costs of facility construction and expansion efforts, or related job creation objectives for the “Smithfield Facility” (see Note 19, Leases). The Company achieved both milestones during 2025 and
received the $5,000 total cash payments. Amounts received are included in cash flows from operating activities in the consolidated statements of cash flows. The Company recorded $1,139 of grant income related to this grant in 2025. As of December 31, 2025, $3,861 of deferred income is included in accrued expenses and other current liabilities on the consolidated balance sheets.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
About Revenue Disclosures
Revenue disclosures under ASC 606 explain how a company identifies performance obligations, allocates transaction prices, and determines when revenue is recognized. This section is essential for understanding whether reported revenue reflects genuine economic activity or aggressive accounting choices. Analysts examine the mix of point-in-time versus over-time recognition, which directly affects revenue timing and comparability.
Key signals: rising contract liabilities (deferred revenue) suggest strong future revenue visibility, while declining contract assets may indicate slowing project milestones. Watch for variable consideration estimates — rebates, returns, and performance bonuses that require management judgment. Significant changes in disaggregated revenue by geography or product line can reveal shifting business mix before it appears in headline numbers. Compare revenue growth against contract liability growth to assess sustainability, and scrutinize any changes in the timing of recognition that coincide with earnings pressure.